| Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia Y Gocho, J Liu, J Hu, W Yang, NV Dharia, J Zhang, H Shi, G Du, A John, ... Nature cancer 2 (3), 284-299, 2021 | 87 | 2021 |
| Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia J Hu, J Jarusiewicz, G Du, G Nishiguchi, S Yoshimura, JC Panetta, Z Li, ... Science translational medicine 14 (659), eabo5228, 2022 | 11 | 2022 |
| Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens S Wright, J Hu, H Wang, J Hyle, Y Zhang, G Du, MY Konopleva, ... Proceedings of the National Academy of Sciences 120 (16), e2220134120, 2023 | 4 | 2023 |
| Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia S Yoshimura, JC Panetta, J Hu, L Li, Y Gocho, G Du, A Umezawa, ... Leukemia 37 (6), 1194-1203, 2023 | 3 | 2023 |
| Development of Proteolytic Targeting Chimeras to Target Lck in T-Cell Acute Lymphoblastic Leukemia J Hu, J Jarusiewicz, J Min, L Yang, D Chepyala, M Actis, L Rowland, G Du, ... Blood 138 (Supplement 1), 867-867, 2021 | 2 | 2021 |
| Identification and targeting of treatment resistant progenitor populations in T-cell Acute Lymphoblastic Leukemia K Tan, J Xu, C Chen, T Vincent, P Pölönen, J Hu, S Yoshimura, W Yu, ... Research Square, 2023 | 1 | 2023 |
| Progenitor sub-populations in treatment resistant T-ALL J Xu, C Chen, TL Vincent, P Pölönen, A Elsayed, J Hu, S Yoshimura, ... Blood 140 (Supplement 1), 1724-1726, 2022 | 1 | 2022 |
| Monitoring drug metabolic pathways through extracellular vesicles in mouse plasma X Wu, M Quan, M Hadisurya, J Hu, YK Liu, Y Zhuang, L Li, AB Iliuk, ... PNAS nexus 3 (2), pgae023, 2024 | | 2024 |
| Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia C Chen, J Xu, TL Vincent, W Yu, YY Ding, C Chen, S Kim, E Li, ... Blood 140 (Supplement 1), 1273-1274, 2022 | | 2022 |
| Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Dasatinib and Ponatinib in Lck-Activated T-Cell Acute Lymphoblastic Leukemia S Yoshimura, J Hu, JC Panetta, G Du, L Li, CH Pui, M Konopleva, N Jain, ... Blood 140 (Supplement 1), 8840-8841, 2022 | | 2022 |
| Induced proximity and proteolytic targeting of LCK as a novel therapeutic approach in T-cell leukemia J Hu, J Jarusiewicz, J Min, L Yang, D Chepyala, M Actis, G Du, B Smart, ... Cancer Research 82 (12_Supplement), 423-423, 2022 | | 2022 |
| Interrogating Novel Bromodomain Inhibition Resistance Mechanism in Mllr Leukemia C Li, S Wright, J Hu, Y Zhang, J Hyle, R Lu Blood 138, 26, 2021 | | 2021 |
